Combining Lithium and Anticonvulsants in Bipolar Disorder: A Review

References

• Kupfer DJ, Frank E, Grochocinski VI, Cluss PA, Houck PR, Stapf DA: Demographic and clinical characteristics of individ-uals in a bipolar disorder case registry. J Clin Psychiatry 2002; 63:120–125
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L: Antidepressant-induced mania and cycle ac-celeration: A controversy revisited. Am J Psychiatry 1995; 152:1130–1138
   PubMed Web of Science ®Google Scholar
• Bocchetta A, Chillotti C, Severino G, Ardau R, Del Zompo M: Carbamazepine augmentation in lithium-refractory bipo-lar patients: A prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol 1997; 17:92–96
   Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr, Chou JC, Keck PE, Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treat-ment of outpatients with bipolar I disorder. Divalproex Main-tenance Study Group. Arch Gen Psychiatry 2000; 57:481–489
   PubMed Web of Science ®Google Scholar
• Baldessarini RJ, Tondo L: Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57:187–190
   PubMed Web of Science ®Google Scholar
• Schou M: Suicidal behavior and prophylactic lithium treat-ment of major mood disorders: A review of reviews. Suicide Life Threat Behav 2000; 30:289–293
   PubMed Web of Science ®Google Scholar
• Tondo L, Baldessarini RJ: Reduced suicide risk during lithium maintenance treatment. J Clin Psychiatry 2000; 61 (Suppl 9):97–104
   PubMedGoogle Scholar
• Strakowski SM, McElroy SL, Keck PE: Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, eds. Ph armacoth er-apy for Mood, Anxiety, and Cognitive Disorders. Washington, DC: American Psychiatric Press; 2000:143–157
   Google Scholar
• Nemeroff CB: An ever-increasing pharmacopoeia for the man-agement of patients with bipolar disorder. J Clin Psychiatry 2000; 61 (Suppl 13):19–25
   PubMedGoogle Scholar
• Post RM, Denicoff KD, Frye MA, Leverich GS, Cora-Locatelli G, Kimbrell TA: Long-term outcome of anticonvulsants in af-fective disorders. In: Goldberg JF, Harrow M, eds. Bipolar Dis-orders. Washington, DC: American Psychiatric Press; 1999:85–114
   Google Scholar
• Kramlinger KG, Post RM: Adding lithium carbonate to car-bamazepine: Antimanic efficacy in treatment-resistant mania. Acta Psychiatr Scand 1989; 79:378–385
   PubMedGoogle Scholar
• Kramlinger KG, Post RM: The addition of lithium to carba-mazepine: Antidepressant efficacy in treatment-resistant de-pression. Arch Gen Psychiatry 1989; 46:794–800
   PubMedGoogle Scholar
• Kramlinger KG, Post RM: Addition of lithium carbonate to carbamazepine: Hematological and thyroid effects. Am J Psy-chiatry 1990; 147:615–620
   PubMed Web of Science ®Google Scholar
• Physician's Desk Reference. Montvale, NJ: Medical Eco-nomics; 2002:432
   Google Scholar
• Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP: The expert consensus guideline series: Medication treatment of bipolar disorders 2000. Postgraduate Medicine Special Re-port 2000(April):1–104
   Google Scholar
• Sharma V, Persad E, Mazmanian D, Karunaratne K: Treatment of rapid-cycling bipolar disorder with combination therapy of valproate and lithium. Can J Psychiatry 1993; 38:137–139
   PubMedGoogle Scholar
• Schneider AL, Wilcox CS: Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients. I Affect Disord 1998; 47:201–205
   PubMed Web of Science ®Google Scholar
• McCoy L, Votolato NA, Schwarzkopf SB, Nasrallah HA: Clin-ical correlates of valproate augmentation in refractory bipolar disorder. Ann Clin Psychiatry 1993; 5:29–33
   Google Scholar
• Calabrese JR, Shelton MD, Bowden CL, Rapport DJ, Suppes T, Shirley ER, Kimmel SE, Caban SJ: Bipolar rapid cycling: Focus on depression as its hallmark. J Clin Psychiatry 2001; 62 (Suppl 14):34–41
   Google Scholar
• Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, Keller MB: A pilot study of lithium carbonate plus divalproex for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997; 58:95–99
   PubMed Web of Science ®Google Scholar
• Solomon DA, Keitner GI, Ryan CE, Miller IW: Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: A review. J Clin Psychopharmacol 1998; 18:38–49
   PubMed Web of Science ®Google Scholar
• Denicoff KD, Smith-Jackson BE, Bryan AL, Ali SO, Post RM: Valproate prophylaxis in a prospective clinical trial of refrac-tory bipolar disorder. Am J Psychiatry 1997; 154:1456–1458
   PubMedGoogle Scholar
• Hachad H, Ragueneau-Majlessi, Levy RH: New antiepileptic drugs: Review on drug interactions. Ther Drug Monit 2002; 24:91–103
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Shelton MD, Rapport DJ, Kimmel SE: Bipolar disorders and the effectiveness of novel anticonvulsants. J Clin Psychiatry 2002; 63 (Suppl 3):5–9.
   PubMedGoogle Scholar
• Emrich HM: Studies with oxcarbazepine (Trileptal) in acute mania. Int Clin Psychopharmacol 1990; 5:83–88
   PubMedGoogle Scholar
• Calabrese JR, Rapport DJ, Shelton MD, Kujawa M, Kimmel SE: Clinical studies on the use of lamotrigine in bipolar disor-der. Neuropsychobiology 1998; 38:185–191
   Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, Rhodes LJ, Keck PE, Jr, Cookson J, Anderson J, Bolden-Watson C, Ascher J, Monaghan E, Zhou J: The efficacy of lamotrigine in rapid cy-cling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry 1999; 45:953–958
   PubMed Web of Science ®Google Scholar
• Fatemi SH, Rapport DJ, Calabrese JR, Thuras P: Lamotrig-ine in rapid-cycling bipolar disorder. J Clin Psychiatry 1997; 58:522–527
   PubMed Web of Science ®Google Scholar
• Kotler M, Matar MA: Lamotrigine in the treatment of resistant bipolar disorder. Clin Neuropharmacol 1998; 21:65–67
   Google Scholar
• Sporn I, Sachs G: The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17:185–189
   PubMed Web of Science ®Google Scholar
• Fogelson DL, Sternbach H: Lamotrigine treatment of rapid cycling bipolar disorder. J Clin Psychiatry 1997; 58:271–273
   PubMedGoogle Scholar
• Zerjav-Lacombe S, Tabarsi E: Lamotrigine: A review of clini-cal studies in bipolar disorders. Can .1 Psychiatry 2001; 46:328–333
   Google Scholar
• Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD: Safety of long-term lamotrigine in epilepsy. Epilepsia 1997; 38:881–886
   PubMed Web of Science ®Google Scholar
• Messenheimer JA, Giorgi L, Risner ME: The tolerability of lamotrigine in children. Drug Saf 2000; 22:303–312
   PubMed Web of Science ®Google Scholar
• Chen C, Veronese L, Yin Y: The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 2000; 50:193–195
   PubMed Web of Science ®Google Scholar
• Post RM, Frye MA, Denicoff KD, Speer AM, Weiss SRB, Leverich GS: Preliminary algorithms for treatment-resistant bipolar depression. In: Amsterdam JD, Hornig M, Nierenberg A, eds. Treatment-Resistant Mood Disorders. London: Cambridge University Press; 2001:350–404
   Google Scholar
• McElroy SL, Suppes T, Keck PE, Frye MA, Denicoff KD, Altshuler LL, Brown ES, Nolen WA, Kupka RW, Rochussen J, Leverich GS, Post RM: Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47:1025–1033
   PubMed Web of Science ®Google Scholar
• Grunze HC, Normann C, Langosch .1, Schaefer M, Amann B, Sterr A, Schloesser S, Kleindienst N, Walden J: Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry 2001; 62: 464–468
   Google Scholar
• Chengappa KNR, Gershon S, Levine J: The evolving role of topiramate among other mood stabilizers in the man-agement of bipolar disorder. Bipolar Disorders 2001; 3:215–232
   PubMed Web of Science ®Google Scholar
• Doose DR, Kohl KA, Desai-Krieger D, Natarajan J, van Kammen PP: The efficacy of topiramate on lithium-serum concentration. Presented at the 37h Annual Meeting of the American College of Neuropsychopharmacology, Las Croabas, Puerto Rico, December 1998
   Google Scholar
• Chengappa KN, Rathore D, Levine J, Atzert R, Solai L, Parepally H, Levin H, Moffa N, Delaney J, Brar JS: Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disorders 1999; 1:42–53
   PubMedGoogle Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607–614
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Bipolar Disorders 2000; 2:249–255
   PubMed Web of Science ®Google Scholar
• Jacobson SA, Pies RW, Greenblatt DJ: Handbook of Geriatric Psychopharmacology. Washington, DC: American Psychiatric Press; 2002
   Google Scholar
• Ghaemi SN, Ko JY: Polypharmacy of bipolar disorder. In: Ghaemi SN, ed. Polypharmacy in Psychiatry. New York: Marcel Dekker; 2002:35–78
   Google Scholar
• Greil W, Kruger R, Rosnagl G, et al.: Prophylactic treatment of affective disorders with carbamazepine and oxcarbazepine: An open, clinical trial. Presented at the 7th World Congress of Psychiatry, Vienna, Austria, July 1983
   Google Scholar